Due to the role of IL-1 in tumor progression [10,11], ANK has been tested in preclinical in vitro and in vivo settings with encouraging results [23,34,35,36], and clinical trials have planned the incorporation of ANK into treatment protocols [62]. The gene discussed is IL1A; the disease is neoplasm.